LCM
HZNP

Laurion Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Laurion Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-250,000
Closed -$2.97M – 2022
2017
Q2 		$2.97M Hold
250,000
– – 0.02% 683
2017
Q1 		$3.69M Buy
+250,000
New +$4.05M 0.03% 489

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Laurion Capital Management's HZNP Position: Q4 2023 in Review

Laurion Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,453,206 shares — an estimated $168M sold.

Laurion Capital Management first reported a position in HZNP in Q3 2014 and held it in 12 quarters. The position peaked at $168M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Laurion Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Laurion Capital Management sold 1,453,206 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $168M.
  • Laurion Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 12 quarters.
  • Laurion Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $168M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.